Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 6, 2011, Pages 620-646

  Yu, Shann S ^a   Ortega, Ryan A ^a   Reagan, Brendan W ^b   Mcpherson, John A ^b   Sung, Hak Joon ^a   Giorgio, Todd D ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYOCARDIAL INFARCTION; ATHEROSCLEROTIC PLAQUE; BLOOD TESTING; CARDIAC ARREST; CARDIAC DEATH; CARDIAC DISEASE; CELLULAR COMPONENTS; CONTRAST AGENT; CORONARY ARTERY DISEASE; CURRENT IMAGING; EMERGING APPLICATIONS; INFLAMMATORY ACTIVITY; KEY DETERMINANTS; LOWER COST; NANOPATTERNING; PHAGOCYTOSE; POTENTIAL SOLUTIONS; RESTENOSIS; SIZE SCALE; STENTING; VASCULAR STRUCTURES;

DISEASES; IMAGING TECHNIQUES; NANOTECHNOLOGY; STENTS; TISSUE;

DIAGNOSIS;

C REACTIVE PROTEIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CD40 ANTIGEN; CHLORDANE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GADOLINIUM; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MACROGOL; MULTI WALLED NANOTUBE; NEUTROPHIL COLLAGENASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PACLITAXEL; RAPAMYCIN; VASCULAR CELL ADHESION MOLECULE 1; NANOMATERIAL;

ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BLOOD EXAMINATION; CORONARY STENT; DRUG ELUTING STENT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; LIGHT SCATTERING; MICROFLUIDICS; MOLECULAR IMAGING; MONONUCLEAR PHAGOCYTE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NANOTECHNOLOGY; NEAR INFRARED SPECTROSCOPY; NEOINTIMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN HEART SURGERY; OPTICAL COHERENCE TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY; RETICULOENDOTHELIAL SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; CORONARY ARTERY DISEASE; NANOMEDICINE; PLAQUE, ATHEROSCLEROTIC;

CORONARY ARTERY DISEASE; HUMANS; NANOMEDICINE; NANOSTRUCTURES; PLAQUE, ATHEROSCLEROTIC;

EID: 84858409066     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.158     Document Type: Review

References (248)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Insull W, Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009, 122:S3-S14.
3. Naghavi M, Falk E. From vulnerable plaque to vulnerable patient. Asymptomatic Atherosclerosis. New York, NY: Humana Press; 2010, 13-38.
4. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part I. Circulation 2003, 107:2274-2279.
5. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
6. Shyy JY, Chien S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002, 91:769-775.
7. Arroyo LH, Lee RT. Mechanisms of plaque rupture: mechanical and biologic interactions. Cardiovasc Res 1999, 41:369-375.
8. Saam T, Hatsukami TS, Takaya N, Chu B, Underhill H, Kerwin WS, Cai J, Ferguson MS, Yuan C. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology 2007, 244:64-77.
9. Van Berkel TJ, De Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 1991, 266:2282-2289.
10. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
11. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005, 25:2255-2264.
12. Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods 2007, 43:207-217.
13. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Kilbride M, Breitbart RE, Chun M, Schonbeck U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899-1904.
14. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004, 94:262-268.
15. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006, 116:59-69.
16. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006, 37:235-239.
17. de Nooijer R, Verkleij CJ, von der Thusen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006, 26:340-346.
18. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
19. Finet G, Ohayon J, Rioufol G. Biomechanical interaction between cap thickness, lipid core composition and blood pressure in vulnerable coronary plaque: impact on stability or instability. Coron Artery Dis 2004, 15:13-20.
20. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
21. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
22. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation 1991, 83:1764-1770.
23. Beaussier H, Masson I, Collin C, Bozec E, Laloux B, Calvet D, Zidi M, Boutouyrie P, Laurent S. Carotid plaque, arterial stiffness gradient, and remodeling in hypertension. Hypertension 2008, 52:729-736.
24. Tajaddini A, Kilpatrick DL, Vince DG. A novel experimental method to estimate stress-strain behavior of intact coronary arteries using intravascular ultrasound (IVUS). J Biomech Eng 2003, 125:120-123.
25. Kim YS, Galis ZS, Rachev A, Han HC, Vito RP. Matrix metalloproteinase-2 and -9 are associated with high stresses predicted using a nonlinear heterogeneous model of arteries. J Biomech Eng 2009, 131:011009.
26. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ, Krams R, de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006, 113:2744-2753.
27. Douma K, Prinzen L, Slaaf DW, Reutelingsperger CP, Biessen EA, Hackeng TM, Post MJ, van Zandvoort MA. Nanoparticles for optical molecular imaging of atherosclerosis. Small 2009, 5:544-557.
28. Trivedi RA, Mallawarachi C, UK-I JM, Graves MJ, Horsley J, Goddard MJ, Brown A, Wang L, Kirkpatrick PJ, Brown J, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006, 26:1601-1606.
29. Holzapfel GA, Sommer G, Regitnig P. Anisotropic mechanical properties of tissue components in human atherosclerotic plaques. J Biomech Eng 2004, 126:657-665.
30. Richardson PD. Biomechanics of plaque rupture: progress, problems, and new frontiers. Ann Biomed Eng 2002, 30:524-536.
31. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988, 78:1157-1166.
32. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992, 69:729-732.
33. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004, 110:1226-1230.
34. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005, 111:143-149.
35. de Weert TT, Ouhlous M, Meijering E, Zondervan PE, Hendriks JM, van Sambeek MR, Dippel DW, van der Lugt A. In vivo characterization and quantification of atherosclerotic carotid plaque components with multidetector computed tomography and histopathological correlation. Arterioscler Thromb Vasc Biol 2006, 26:2366-2372.
36. Das M, Braunschweig T, Muhlenbruch G, Mahnken AH, Krings T, Langer S, Koeppel T, Jacobs M, Gunther RW, Mommertz G. Carotid plaque analysis: comparison of dual-source computed tomography (CT) findings and histopathological correlation. Eur J Vasc Endovasc Surg 2009, 38:14-19.
37. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, Takaya N, Polissar NL, Yuan C. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005, 112:3437-3444.
38. Beduneau A, Ma Z, Grotepas CB, Kabanov A, Rabinow BE, Gong N, Mosley RL, Dou H, Boska MD, Gendelman HE. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One 2009, 4:e4343.
39. Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjornerud A, Fayad ZA, Ahlstrom HK. Clearance of iron oxide particles in rat liver-effect of hydrated particle size and coating material on liver metabolism. Invest Radiol 2006, 41:560-571.
40. Briley-Saebo KC, Mani V, Hyafil F, Cornily JC, Fayad ZA. Fractionated feridex and positive contrast: in vivo MR imaging of atherosclerosis. Magn Reson Med 2008, 59:721-730.
41. Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, Sadat U, Howarth SP, Gillard JH. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009, 29:1001-1008.
42. Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004, 14:1654-1656.
43. Bastus NG, Sanchez-Tillo E, Pujals S, Farrera C, Lopez C, Giralt E, Celada A, Lloberas J, Puntes V. Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano 2009, 3:1335-1344.
44. Simberg D, Park JH, Karmali PP, Zhang WM, Merkulov S, McCrae K, Bhatia SN, Sailor M, Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
45. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, Azure M, Fujimoto A, Isobe S, Matsumoto Y, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008, 52:1847-1857.
46. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, Frederik PM, Daemen MJ, van Engelshoven JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107:2453-2458.
47. Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, Abbate A, Aguinaldo JG, Massey D, Fuster V, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009, 2:637-647.
48. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, Libby P, Swirski FK, Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
49. Trivedi RA, UK-I JM, Graves MJ, Kirkpatrick PJ, Gillard JH. Noninvasive imaging of carotid plaque inflammation. Neurology 2004, 63:187-188.
50. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, Kruth HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008, 172:1112-1126.
51. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004, 39:56-63.
52. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008, 451:953-957.
53. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
54. Giannarelli C, Ibanez B, Cimmino G, Garcia Ruiz JM, Faita F, Bianchini E, Zafar MU, Fuster V, Garcia MJ, Badimon JJ. Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. JACC Cardiovasc Imaging 2010, 3:1256-1264.
55. Manca C, Parenti G, Bellina R, Boni G, Grosso M, Bernini W, Palombo C, Paterni M, Pelosi G, Lanza M, et al. In-111 platelet scintigraphy for the noninvasive detection of carotid plaque thrombosis. Stroke 2001, 32:719-727.
56. Annovazzi A, Bonanno E, Arca M, D'Alessandria C, Marcoccia A, Spagnoli LG, Violi F, Scopinaro F, De Toma G, Signore A. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006, 33:117-126.
57. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818-1824.
58. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276-1282.
59. Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S, Ito K, Yasumura Y, Miyatake K. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000, 35:106-111.
60. Bayturan O, Tuzcu EM, Nicholls SJ, Balog C, Lavoie A, Uno K, Crowe TD, Magyar WA, Wolski K, Kapadia S, et al. Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. JACC Cardiovasc Interv 2009, 2:672-678.
61. Lee SY, Mintz GS, Kim SY, Hong YJ, Kim SW, Okabe T, Pichard AD, Satler LF, Kent KM, Suddath WO, et al. Attenuated plaque detected by intravascular ultrasound: clinical, angiographic, and morphologic features and post-percutaneous coronary intervention complications in patients with acute coronary syndromes. JACC Cardiovasc Interv 2009, 2:65-72.
62. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206.
63. Van Herck J, De Meyer G, Ennekens G, Van Herck P, Herman A, Vrints C. Validation of in vivo plaque characterisation by virtual histology in a rabbit model of atherosclerosis. EuroIntervention 2009, 5:149-156.
64. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, Serruys PW. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005, 46:2038-2042.
65. Serruys PW. Fourth annual American College of Cardiology international lecture: a journey in the interventional field. J Am Coll Cardiol 2006, 47:1754-1768.
66. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, et al. A prospective natural-history study of coronary atherosclerosis. New Engl J Med 2011, 364:226-235.
67. Low AF, Tearney GJ, Bouma BE, Jang IK. Technology Insight: optical coherence tomography-current status and future development. Nat Clin Pract Cardiovasc Med 2006, 3:154-162, quiz 172.
68. Stamper D, Weissman NJ, Brezinski M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol 2006, 47:C69-C79.
69. Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I, Flueckiger S, Kronen P, Sidler M, Klein K, et al. Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 2010, 31:1792-1801.
70. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005, 46:1209-1218.
71. Fuster V, Corti R, Fayad ZA, Schwitter J, Badimon JJ. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. J Thromb Haemost 2003, 1:1410-1421.
72. Sirol M, Fuster V, Fayad ZA. Plaque imaging and characterization using magnetic resonance imaging: towards molecular assessment. Curr Mol Med 2006, 6:541-548.
73. Moreno PR. Vulnerable plaque: definition, diagnosis, and treatment. Cardiol Clin 2010, 28:1-30.
74. Sathyanarayana S, Schar M, Kraitchman DL, Bottomley PA. Towards real-time intravascular endoscopic magnetic resonance imaging. JACC Cardiovasc Imaging 2010, 3:1158-1165.
75. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, Hazle JD, Halas NJ, West JL. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003, 100:13549-13554.
76. Luker GD, Luker KE. Optical imaging: current applications and future directions. J Nucl Med 2008, 49:1-4.
77. Goldstein JA, Grines C, Fischell T, Virmani R, Rizik D, Muller J, Dixon SR. Coronary embolization following balloon dilation of lipid-core plaques. JACC Cardiovasc imaging 2009, 2:1420-1424.
78. Madden SP, Sum ST, Muller JE. Assessment of coronary stenosis with near infrared spectroscopy. In: Escaned J, Serruys P, eds. Coronary Stenosis Imaging, Structure, and Physiology. Toulouse: PCR Publishing; 2010.
79. Caplan JD, Waxman S, Nesto RW, Muller JE. Near-infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol 2006, 47:C92-C96.
80. Gardner CM, Tan H, Hull EL, Lisauskas JB, Sum ST, Meese TM, Jiang C, Madden SP, Caplan JD, Burke AP, et al. Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc Imaging 2008, 1:638-648.
81. Moreno PR, Lodder RA, Purushothaman KR, Charash WE, O'Connor WN, Muller JE. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation 2002, 105:923-927.
82. Schultz CJ, Serruys PW, van der Ent M, Ligthart J, Mastik F, Garg S, Muller JE, Wilder MA, van de Steen AFW, Regar E. First-in-man clinical use of combined near-infrared spectroscopy and intravascular ultrasound a potential key to predict distal embolization and no-reflow? J Am Coll Cardiol 2010, 56:314-314.
83. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002, 8:1257-1262.
84. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 2006, 47:1328-1338.
85. Ni M, Chen WQ, Zhang Y. Animal models and potential mechanisms of plaque destabilisation and disruption. Heart 2009, 95:1393-1398.
86. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, Marinelli B, Aikawa E, Pittet MJ, Swirski FK, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 2009, 29:1444-1451.
87. Ma LL, Feldman MD, Tam JM, Paranjape AS, Cheruku KK, Larson TA, Tam JO, Ingram DR, Paramita V, Villard JW, et al. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 2009, 3:2686-2696.
88. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A, Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem 2002, 13:122-127.
89. Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA, Jr. Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest 2006, 86:599-609.
90. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
91. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, Ruoslahti E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 2009, 106:9815-9819.
92. Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y, Fisher EA, Fayad ZA. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4:1437-1444.
93. Cormode DP, Roessl E, Thran A, Skajaa T, Gordon RE, Schlomka JP, Fuster V, Fisher EA, Mulder WJ, Proksa R, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 2010, 256:774-782.
94. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316-16317.
95. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008, 8:3715-3723.
96. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, UK-I JM, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53:2039-2050.
97. Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, Aikawa M. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010, 122:1707-1715.
98. Wang B, Yantsen E, Larson T, Karpiouk AB, Sethuraman S, Su JL, Sokolov K, Emelianov SY. Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. Nano Lett 2009, 9:2212-2217.
99. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13:636-641.
100. Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med 2009, 50:959-965.
101. Harris TJ, von Maltzahn G, Lord ME, Park JH, Agrawal A, Min DH, Sailor MJ, Bhatia SN. Protease-triggered unveiling of bioactive nanoparticles. Small 2008, 4:1307-1312.
102. Schellenberger E, Rudloff F, Warmuth C, Taupitz M, Hamm B, Schnorr J. Protease-specific nanosensors for magnetic resonance imaging. Bioconjug Chem 2008, 19:2440-2445.
103. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117:3206-3215.
104. Briley-Saebo KC, Cho YS, Shaw PX, Ryu SK, Mani V, Dickson S, Izadmehr E, Green S, Fayad ZA, Tsimikas S. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol 2011, 57:337-347.
105. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, Reutelingsperger CP, Fayad ZA, Mulder WJ, Nicolay K. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem 2010, 21:1794-1803.
106. Lee D, Khaja S, Velasquez-Castano JC, Dasari M, Sun C, Petros J, Taylor WR, Murthy N. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater 2007, 6:765-769.
107. Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006, 56:601-610.
108. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961-966.
109. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
110. Tsourkas A, Shinde-Patil VR, Kelly KA, Patel P, Wolley A, Allport JR, Weissleder R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug Chem 2005, 16:576-581.
111. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005, 96:327-336.
112. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with α(v)β3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
113. Tomokiyo R, Jinnouchi K, Honda M, Wada Y, Hanada N, Hiraoka T, Suzuki H, Kodama T, Takahashi K, Takeya M. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis 2002, 161:123-132.
114. Guray U, Erbay AR, Guray Y, Yilmaz MB, Boyaci AA, Sasmaz H, Korkmaz S, Kutuk E. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004, 96:235-240.
115. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999, 41:443-449.
116. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983, 52:223-261.
117. Nagaoka K, Takahara K, Tanaka K, Yoshida H, Steinman RM, Saitoh S, Akashi-Takamura S, Miyake K, Kang YS, Park CG, et al. Association of SIGNR1 with TLR4-MD-2 enhances signal transduction by recognition of LPS in gram-negative bacteria. Int Immunol 2005, 17:827-836.
118. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, Amirbekian V, Tang C, Chin PT, Nicolay K, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007, 58:1164-1170.
119. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJP, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, et al. Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. J Am Coll Cardiol 2010, 56:946-955.
120. Woo K, Hong J, Choi S, Lee HW, Ahn JP, Kim CS, Lee SW. Easy synthesis and magnetic properties of iron oxide nanoparticles. Chem Mater 2004, 16:2814-2818.
121. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002, 298:1759-1762.
122. Park J, Joo J, Kwon SG, Jang Y, Hyeon T. Synthesis of monodisperse spherical nanocrystals. Angew Chem Int Ed 2007, 46:4630-4660.
123. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol 2006, 8:201-207.
124. Paranjape AS, Kuranov R, Baranov S, Ma LL, Villard JW, Wang T, Sokolov KV, Feldman MD, Johnston KP, Milner TE. Depth resolved photothermal OCT detection of macrophages in tissue using nanorose. Biomed Opt Exp 2010, 1:2-16.
125. Yu SS, Scherer RL, Ortega RA, Bell CS, O'Neil CP, Hubbell JA, Giorgio TD. Enzymatic- and temperature-sensitive controlled release of ultrasmall superparamagnetic iron oxides (USPIOs). J Nanobiotechnol 2011, 9:7.
126. Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E, Harney RL, Hammett-Stabler C, Lepp S, Li Y, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009, 31:688-694.
127. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, Kohler RH, Shi GP, Libby P, Weissleder R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007, 115:2292-2298.
128. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102:576-583.
129. Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH, Long CJ, Jackson CL. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006, 26:851-856.
130. Li W, Yuan XM. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci 2004, 1030:427-433.
131. Tung CH, Bredow S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem 1999, 10:892-896.
132. Lakowicz JR. Principles of Fluorescence Spectroscopy. 3rd ed. New York: Springer; 2006.
133. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114:55-62.
134. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002, 105:2766-2771.
135. Altinoglu EI, Adair JH. Near infrared imaging with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:461-477.
136. Chang E, Miller JS, Sun J, Yu WW, Colvin VL, Drezek R, West JL. Protease-activated quantum dot probes. Biochem Biophys Res Commun 2005, 334:1317-1321.
137. Sun J, Fu K, Zhu M-Q, Bickford L, Post E, Drezek R. Near-infrared quantum dot contrast agents for fluorescence tissue imaging: a phantom study. Curr Nanosci 2009, 5:160-166.
138. Smith AM, Nie S. Bright and compact alloyed quantum dots with broadly tunable near-infrared absorption and fluorescence spectra through mercury cation exchange. J Am Chem Soc 2010, 133:24-26.
139. Ma Q, Su X. Near-infrared quantum dots: synthesis, functionalization and analytical applications. Analyst 2010, 135:1867-1877.
140. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, Parker JA, Mihaljevic T, Laurence RG, Dor DM, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22:93-97.
141. Bailey RE, Strausburg JB, Nie S. A new class of far-red and near-infrared biological labels based on alloyed semiconductor quantum dots. J Nanosci Nanotechnol 2004, 4:569-574.
142. Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WC. In vivo quantum-dot toxicity assessment. Small 2010, 6:138-144.
143. Chang E, Thekkek N, Yu WW, Colvin VL, Drezek R. Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small 2006, 2:1412-1417.
144. Sewell SL, Giorgio TD. Synthesis and enzymatic cleavage of dual-ligand quantum dots. Mater Sci Eng C Mater Biol Appl 2009, 29:1428-1432.
145. Smith R, Sewell SL, Giorgio TD. Proximity-activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavage. Int J Nanomed 2008, 3:95-103.
146. Sewell SL, Giorgio TD. Surface functionalized nanoparticles for proximity-activated detection and imaging of breast cancer. Cancer Res 2009, 69:348s.
147. Guyton AC, Hall JE. Textbook of Medical Physiology, 11th ed. Philadelphia: Elsevier Saunders; 2006.
148. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649-1659.
149. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Delivery Rev 1995, 17:31-48.
150. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788:2259-2266.
151. Kirkland-York S, Zhang Y, Smith AE, York AW, Huang F, McCormick CL. Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition-fragmentation chain transfer polymers. Biomacromolecules 2010, 11:1052-1059.
152. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007, 25:667-680.
153. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Contr Rel 2000, 65:271-284.
154. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
155. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005, 23:1418-1423.
156. Senpan A, Caruthers SD, Rhee I, Mauro NA, Pan D, Hu G, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA, et al. Conquering the dark side: colloidal iron oxide nanoparticles. Acs Nano 2009, 3:3917-3926.
157. Erogbogbo F, Yong K-T, Roy I, Xu G, Prasad PN, Swihart MT. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. Acs Nano 2008, 2:873-878.
158. McIntyre JO, Scherer RL, Matrisian LM. Near-infrared optical proteolytic beacons for in vivo imaging of matrix metalloproteinase activity. Methods Mol Biol 2010, 622:279-304.
159. Scherer RL, VanSaun MN, McIntyre JO, Matrisian LM. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol Imaging 2008, 7:118-131.
160. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47:C19-C31.
161. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
162. Hirsch LR, Halas NJ, West JL. Whole-blood immunoassay facilitated by gold nanoshell-conjugate antibodies. Methods Mol Biol 2005, 303:101-111.
163. Soman CP, Giorgio TD. Quantum dot self-assembly for protein detection with sub-picomolar sensitivity. Langmuir 2008, 24:4399-4404.
164. Kim KS, Park JK. Magnetic force-based multiplexed immunoassay using superparamagnetic nanoparticles in microfluidic channel. Lab Chip 2005, 5:657-664.
165. Perez JM, Josephson L, O'Loughlin T, Hogemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002, 20:816-820.
166. Hirsch LR, Jackson JB, Lee A, Halas NJ, West JL. A whole blood immunoassay using gold nanoshells. Anal Chem 2003, 75:2377-2381.
167. Blinka E, Loeffler K, Hu Y, Gopal A, Hoshino K, Lin K, Liu X, Ferrari M, Zhang JX. Enhanced microcontact printing of proteins on nanoporous silica surface. Nanotechnology 2010, 21:415302.
168. Agrawal A, Sathe T, Nie S. Single-bead immunoassays using magnetic microparticles and spectral-shifting quantum dots. J Agric Food Chem 2007, 55:3778-3782.
169. Bulte JWM, Modo MMJ, Perez JM, Kaittanis C. Magnetic nanosensors for probing molecular interactions. In: Ferrari M, ed. Nanoparticles in Biomedical Imaging, Vol 102. New York: Springer; 2008, 183-197.
170. Ibraimi F, Kriz D, Lu M, Hansson L-O, Kriz K. Rapid one-step whole blood C-reactive protein magnetic permeability immunoassay with monoclonal antibody conjugated nanoparticles as superparamagnetic labels and enhanced sedimentation. Anal Bioanal Chem 2006, 384:651-657.
171. Ng AH, Uddayasankar U, Wheeler AR. Immunoassays in microfluidic systems. Anal Bioanal Chem 2010, 397:991-1007.
172. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW, Wong J, Gage C, Furmaga WB, Redding SW, et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009, 24:3622-3629.
173. Sia SK, Whitesides GM. Microfluidic devices fabricated in poly(dimethylsiloxane) for biological studies. Electrophoresis 2003, 24:3563-3576.
174. McClain MA, Culbertson CT, Jacobson SC, Ramsey JM. Flow cytometry of Escherichia coli on microfluidic devices. Anal Chem 2001, 73:5334-5338.
175. Wlodkowic D, Faley S, Zagnoni M, Wikswo JP, Cooper JM. Microfluidic single-cell array cytometry for the analysis of tumor apoptosis. Anal Chem 2009, 81:5517-5523.
176. Adams ML, Enzelberger M, Quake S, Scherer A. Microfluidic integration on detector arrays for absorption and fluorescence micro-spectrometers. Sensors Actuat A Phys 2003, 104:25-31.
177. Haun JB, Yoon TJ, Lee H, Weissleder R. Magnetic nanoparticle biosensors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:291-304.
178. Lee H, Sun E, Ham D, Weissleder R. Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med 2008, 14:869-874.
179. Chastek TQ, Beers KL, Amis EJ. Miniaturized dynamic light scattering instrumentation for use in microfluidic applications. Rev Sci Instrum 2007, 78:072201.
180. Chastek TQ, Iida K, Amis EJ, Fasolka MJ, Beers KL. A microfluidic platform for integrated synthesis and dynamic light scattering measurement of block copolymer micelles. Lab Chip 2008, 8:950-957.
181. Soman C, Giorgio T. Sensitive and multiplexed detection of proteomic antigens via quantum dot aggregation. Nanomed: Nanotechnol Biol Med 2009, 5:402-409.
182. Wyatt PJ. Light-Scattering and the absolute characterization of macromolecules. Anal Chim Acta 1993, 272:1-40.
183. Oden M, Mirabal Y, Epstein M, Richards-Kortum R. Engaging undergraduates to solve global health challenges: a new approach based on bioengineering design. Ann Biomed Eng 2010, 38:3031-3041.
184. Bruls DM, Evers TH, Kahlman JAH, van Lankvelt PJW, Ovsyanko M, Pelssers EGM, Schleipen JJHB, de Theije FK, Verschuren CA, van der Wijk T, et al. Rapid integrated biosensor for multiplexed immunoassays based on actuated magnetic nanoparticles. Lab Chip 2009, 9:3504-3510.
185. Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, Kinane DF, Novak MJ, Steinhubl S, Acosta S, et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009, 55:1530-1538.
186. Lavigne JJ, Savoy S, Clevenger MB, Ritchie JE, McDoniel B, Yoo S-J, Anslyn EV, McDevitt JT, Shear JB, Neikirk D. Solution-based analysis of multiple analytes by a sensor array: toward the development of an "electronic tongue". J Am Chem Soc 1998, 120:6429-6430.
187. Buch M, Rishpon J. An electrochemical immunosensor for C-reactive protein based on multi-walled carbon nanotube-modified electrodes. Electroanalysis 2008, 20:2592-2594.
188. Wang J. Carbon-nanotube based electrochemical biosensors: a review. Electroanalysis 2005, 17:7-14.
189. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61-68.
190. de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994, 127:643-651.
191. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988, 78:1121-1127.
192. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987, 316:701-706.
193. Moliterno DJ. Healing achilles-sirolimus versus paclitaxel. N Engl J Med 2005, 353:724-727.
194. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB, 3rd. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992, 20:467-474.
195. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents-quantitative angiographic assessment. J Am Coll Cardiol 1993, 21:1166-1174.
196. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis. a serial intravascular ultrasound study. Circulation 1996, 94:1247-1254.
197. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004, 364:583-591.
198. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947.
199. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
200. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006, 27:2784-2814.
201. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007, 115:1440-1455, discussion 1455.
202. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019.
203. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005, 294:819-825.
204. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010, 56:1783-1793.
205. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001, 103:2816-2821.
206. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003, 41:1283-1288.
207. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, Leon MB, Fink S, Marin L, Lansky AJ. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003, 92: 463-466.
208. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010, 362:1663-1674.
209. Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, Schulz S, Mehilli J. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009, 95: 1489-1494.
210. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schomig A, Kastrati A. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009, 30: 923-931.
211. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000, 102:399-404.
212. Tsuji T, Tamai H, Igaki K, Hsu Y-S, Kosuga KMO, Nakamura T, Fujita S. Four-year follow-up of the biodegradable stent (IGAKI-TAMAI Stent). Circ J 2004, 68:135.
213. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007, 369:1869-1875.
214. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008, 371: 899-907.
215. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373:897-910.
216. Jiang W-W, Su S-H, Eberhart RC, Tang L. Phagocyte responses to degradable polymers. J Biomed Mater Res A 2007, 82A:492-497.
217. Ramcharitar S, Gonzalo N, van Geuns RJ, Garcia-Garcia HM, Wykrzykowska JJ, Ligthart JMR, Regar E, Serruys PW. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol 2009, 6:374-378.
218. O'Brien B, Carroll W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: A review. Acta Biomater 2009, 5: 945-958.
219. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation 2004, 109:701-705.
220. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue ZY, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113.
221. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans-delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
222. Tada DB, Singh S, Nagesha D, Jost E, Levy CO, Gultepe E, Cormack R, Makrigiorgos GM, Sridhar S. Chitosan film containing Poly(D, L-Lactic-Co-glycolic acid) nanoparticles: a platform for localized dual-drug release. Pharma Res 2010, 27:1738-1745.
223. Jayagopal A, Sussman EM, Shastri VP. Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans Nanobiosci 2008, 7:28-34.
224. Jin C, Bai L, Wu H, Song W, Guo GZ, Dou KF. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharma Res 2009, 26:1776-1784.
225. Ranganath SH, Kee I, Krantz WB, Chow PKH, Wang CH. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharma Res 2009, 26:2101-2114.
226. Bhargava B, Reddy NK, Karthikeyan G, Raju R, Mishra S, Singh S, Waksman R, Virmani R, Somaraju B. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Cathet Cardiovasc Intervent 2006, 67:698-702.
227. Kushwaha M, Anderson JM, Bosworth CA, Andukuri A, Minor WP, Lancaster JR, Anderson PG, Brott BC, Jun HW. A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. Biomaterials 2010, 31:1502-1508.
228. Andukuri A, Minor WP, Kushwaha M, Anderson JM, Jun HW. Effect of endothelium mimicking self-assembled nanomatrices on cell adhesion and spreading of human endothelial cells and smooth muscle cells. Nanomed Nanotechnol Biol Med 2010, 6: 289-297.
229. Decher G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277: 1232-1237.
230. Soike T, Streff AK, Guan CX, Ortega R, Tantawy M, Pino C, Shastri VP. Engineering a material surface for drug delivery and imaging using layer-by-layer assembly of functionalized nanoparticles. Adv Mater 2010, 22:1992.
231. Weber N, Pesnell A, Bolikal D, Zeltinger J, Kohn J. Viscoelastic properties of fibrinogen adsorbed to the surface of biomaterials used in blood-contacting medical devices. Langmuir 2007, 23: 3298-3304.
232. Otsuka M, Tanimoto S, Sianos G, Kukreja N, Weustink AC, Serruys PW, De Feyter PJ. "Radio-lucent" and "radio-opaque" coronary stents characterized by multislice computed tomography. Int J Cardiol 2009, 132:E8-E10.
233. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007, 115: 1051-1058.
234. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369: 667-678.
235. 2 nanotubes on endothelial function and smooth muscle proliferation. Biomaterials 2009, 30:1268-1272.
236. Lu J, Rao MP, MacDonald NC, Khang D, Webster TJ. Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features. Acta Biomater 2008, 4:192-201.
237. Miller DC, Thapa A, Haberstroh KM, Webster TJ. Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features. Biomaterials 2004, 25: 53-61.
238. Fine E, Zhang L, Fenniri H, Webster TJ. Enhanced endothelial cell functions on rosette nanotube-coated titanium vascular stents. Int J Nanomed 2009, 4:91-97.
239. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004, 44:733-739.
240. Lu J, Khang D, Webster TJ. Greater endothelial cell responses on submicron and nanometer rough titanium surfaces. J Biomed Mater Res A 2010, 94A:1042-1049.
241. Khang D, Kim SY, Liu-Snyder P, Palmore GTR, Durbin SM, Webster TJ. Enhanced fibronectin adsorption on carbon nanotube/poly(carbonate) urethane: independent role of surface nano-roughness and associated surface energy. Biomaterials 2007, 28: 4756-4768.
242. Loya MC, Brammer KS, Choi C, Chen LH, Jin SH. Plasma-induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. Acta Biomater 2010, 6:4589-4595.
243. Brammer KS, Choi C, Oh S, Cobb CJ, Connelly LS, Loya M, Kong SD, Jin S. Antibiofouling, sustained antibiotic release by Si nanowire templates. Nano Lett 2009, 9:3570-3574.
244. Samaroo HD, Lu J, Webster TJ. Enhanced endothelial cell density on NiTi surfaces with sub-macron to nanometer roughness. Int J Nanomed 2008, 3: 75-82.
245. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cathet Cardiovasc Intervent 2003, 60:399-407.
246. Buxton DB. Current status of nanotechnology approaches for cardiovascular disease: a personal perspective. WIREs Nanomed Nanobiotechnol 2009, 1:149-155.
247. Jarzyna PA, Gianella A, Skajaa T, Knudsen G, Deddens LH, Cormode DP, Fayad ZA, Mulder WJM. Multifunctional imaging nanoprobes. WIREs Nanomed Nanobiotechnol 2010, 2:138-150.
248. Puskas JE, Muñoz-Robledo LG, Hoerr RA, Foley J, Schmidt SP, Evancho-Chapman M, Dong J, Frethem C, Haugstad G. Drug eluting stent coatings. WIREs Nanomed Nanobiotechnol 2009, 1:451-462.